Stockscreener 앱 받기
13.84
3.01%
-0.43
시간 외 거래:
13.27
-0.57
-4.12%
전일 마감가:
$14.27
열려 있는:
$14.24
하루 거래량:
1.16M
Relative Volume:
0.79
시가총액:
$1.96B
수익:
-
순이익/손실:
$-42.76M
주가수익비율:
-43.14
EPS:
-0.3208
순현금흐름:
$-42.09M
1주 성능:
-5.34%
1개월 성능:
+22.15%
6개월 성능:
+31.43%
1년 성능:
+110.02%
1일 변동 폭
$13.51
$14.57
1주일 범위
$13.51
$15.10
52주 변동 폭
$5.3801
$16.12
트레비 테라퓨틱스 Stock (TRVI) Company Profile
명칭
Trevi Therapeutics Inc
전화
203-304-2499
주소
195 CHURCH STREET, NEW HAVEN, CT
Compare TRVI vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TRVI
Trevi Therapeutics Inc
|
13.84 | 2.03B | 0 | -42.76M | -42.09M | -0.3208 |
VRTX
Vertex Pharmaceuticals Inc
|
430.14 | 108.36B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
731.77 | 78.05B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
775.03 | 48.74B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
302.11 | 41.16B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
298.16 | 33.17B | 5.36B | 287.73M | 924.18M | 2.5229 |
트레비 테라퓨틱스 Stock (TRVI) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-11-13 | 개시 | Leerink Partners | Outperform |
| 2025-08-21 | 개시 | Morgan Stanley | Overweight |
| 2025-07-01 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-05-28 | 개시 | H.C. Wainwright | Buy |
| 2025-03-10 | 재확인 | Needham | Buy |
| 2025-03-10 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2024-12-12 | 재확인 | H.C. Wainwright | Buy |
| 2024-09-09 | 재개 | Leerink Partners | Outperform |
| 2024-08-30 | 개시 | H.C. Wainwright | Buy |
| 2024-08-30 | 개시 | Raymond James | Outperform |
| 2024-06-13 | 개시 | Rodman & Renshaw | Buy |
| 2023-04-12 | 개시 | B. Riley Securities | Buy |
| 2022-11-22 | 개시 | SVB Leerink | Outperform |
| 2019-06-03 | 개시 | BMO Capital Markets | Outperform |
| 2019-06-03 | 개시 | Needham | Buy |
| 2019-06-03 | 개시 | SVB Leerink | Outperform |
| 2019-06-03 | 개시 | Stifel | Buy |
모두보기
트레비 테라퓨틱스 주식(TRVI)의 최신 뉴스
Clinical-stage biotech Trevi sets May 5 webcast for Q1 results - Stock Titan
Trevi Therapeutics to Report First Quarter 2026 Financial Results and Provide a Corporate Update on May 5, 2026 - GlobeNewswire
Trevi Therapeutics to Report Third Quarter 2024 Financial Results and Provide a Corporate Update on November 6, 2024 - Quantisnow
Trevi Therapeutics launches $150M public stock offering - MSN
TRVI stock’s five-day rally pushes it to an all-time high – here’s what’s happening - MSN
Peregrine Capital Management LLC Lowers Stake in Trevi Therapeutics, Inc. $TRVI - MarketBeat
Trevi lines up a May 7 investor day and May 12 conference webcast - Stock Titan
New Haven-based Trevi Therapeutics raises $173M in public offering - Hartford Business Journal
Trevi Therapeutics (TRVI) Stock: Is It Holding Support | Q4 2025: Earnings Beat EstimatesEquity Raise - Cổng thông tin điện tử Tỉnh Sơn La
Did Trevi’s US$173 Million Raise and Share Expansion Just Reshape Trevi Therapeutics' (TRVI) Investment Narrative? - Yahoo Finance
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Receives Consensus Recommendation of "Buy" from Brokerages - MarketBeat
TRVI Forecast, Price Target & Analyst Ratings | TREVI THERAPEUTICS INC (NASDAQ:TRVI) - ChartMill
Trevi Therapeutics (NASDAQ: TRVI) asks holders to OK share, equity plan boosts - Stock Titan
[ARS] Trevi Therapeutics, Inc. SEC Filing - Stock Titan
Leerink raises Trevi Therapeutics stock price target on ILD outlook By Investing.com - Investing.com Canada
Trevi Therapeutics Closes $173 Million Share Offering - marketscreener.com
Trevi Therapeutics announces closing of $173 million underwritten offering - marketscreener.com
Trevi Therapeutics Announces Closing Of $173 Million Underwritten Offering - TradingView
Trevi Therapeutics Announces Closing of $173 Million Underwritten Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares - ChartMill
Can Trevi Therapeutics Address The Big Unmet Need In Chronic Cough? - RTTNews
Trevi Therapeutics (TRVI) Stock: Slowing Down? (Breakout Watch) 2026-04-18Trending Picks - Cổng thông tin điện tử tỉnh Tây Ninh
What's Going On With Trevi Therapeutics Stock? - Sahm
Netflix, Trevi Therapeutics And Other Big Stocks Moving Lower In Friday's Pre-Market Session - Sahm
TRVI Maintains Buy Rating by D. Boral Capital -- Price Target Un - GuruFocus
Trevi Therapeutics Inc (TRVI) Stock Price, Quote, News & History - Benzinga
Trevi Therapeutics (NASDAQ: TRVI) raises ~$150.8M via 11.6M shares - Stock Titan
Trevi Therapeutics launches $150M public stock offering By Investing.com - Investing.com Australia
TRVI Stock’s Five-Day Rally Pushes It To An All-Time High – Here’s What’s Happening - Stocktwits
D. Boral Capital Reiterates "Buy" Rating for Trevi Therapeutics (NASDAQ:TRVI) - MarketBeat
Trevi Therapeutics: Late-Stage Transition Meets Execution Risk (NASDAQ:TRVI) - Seeking Alpha
Trevi Therapeutics (NASDAQ:TRVI) Sees Unusually-High Trading VolumeStill a Buy? - MarketBeat
Trevi Therapeutics Prices Public Offering to Fund Haduvio - TipRanks
TRVI: Key Developments in Recent Offering - GuruFocus
New Haven’s Trevi Therapeutics plans $150M stock offering to fund late-stage drug trials - Hartford Business Journal
Trevi Therapeutics Prices 11.6M-Share Offering at $13; ~$141M Net Proceeds Expected - TradingView
Trevi Therapeutics (NASDAQ: TRVI) raises $150M in stock sale - Stock Titan
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
Trevi Therapeutics Prices $150 Million Common Stock Offering; Shares Down Pre-Bell - marketscreener.com
Trevi Therapeutics Announces Proposed Public Offering of Common Stock - Sahm
Trevi sells 11.6M shares at $13, aiming to raise about $150M - Stock Titan
Trevi Therapeutics stock tumbles on public offering plan By Investing.com - Investing.com Australia
Trevi Therapeutics Expects Offering to Close on or About April 20 >TRVI - Moomoo
Trevi Therapeutics Prices 11.6M Public Offering Shares at $13 Each >TRVI - Moomoo
Trevi Therapeutics prices $150M stock offering at $13 per share By Investing.com - Investing.com South Africa
Trevi Therapeutics prices $150M stock offering at $13 per share - Investing.com
Trevi Therapeutics, Inc. Prices Underwritten Public Offering of 11.6 Million Shares at $13.00 Each - Quiver Quantitative
Trevi Therapeutics Announces Pricing of $150 Million Underwritten Offering of Common Stock - The Manila Times
Trevi Therapeutics announces pricing of $150 million underwritten offering of common stock - marketscreener.com
트레비 테라퓨틱스 (TRVI) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.29%
0.00%
자본화:
|
볼륨(24시간):